The EUA is their attempt to manage the health risk to the population - an investigational vaccine using an entirely unproven novel technology stack poses some unbound risk (likely small), vs the benefit of an effective vaccine. Once we change the dosage, the effectiveness also become unclear, while the risk remains (eg, potential trace contamination with precursors in the lipid carriers triggering shock in a untested population subset. Perhaps prescription statins greatly reduce the effectiveness of the vaccine, etc etc). It's the job of the FDA to err on the side of caution and see risks where we would not. I agree with you that the situation is unprecedented, but I also do not blame the FDA for only working with the data they have. I suspect that Pfizer & Moderna will conduct Phase IV trials with different dosage regimes based on which the FDA can modify the terms of the EUA.
Anyone got any solid insight into this?
> “My concern, as a virologist, is that if you wanted to make a vaccine-resistant strain, what you would do is to build a cohort of partially immunized individuals in the teeth of a highly prevalent viral infection,” Bieniasz told STAT. Even rolling out the vaccine at all when there is so much transmission occurring is far from ideal, he said, suggesting it would have been safer to beat down the amount of virus in circulation before beginning the vaccine deployment.
>“You are essentially maximizing the opportunity for the virus to learn about the human immune system. Learn about antibodies. Learn how to evade them,” he said.
[1] https://www.statnews.com/2021/01/04/britain-takes-a-gamble-w...
Seems clear from my perspective. Two doses are recommend by manufacturers. Anything more or less is pure speculation at best. Why speculate in absence of a way to test your hypothesis?
There are two lines of evidence. The first is empirical. It It appears that one dose of Moderna _is_ highly effective, perhaps 85% or more. Note the treatment-control divergence after about fourteen days [1]. The second is theoretical. From our ample medical experience with other vaccines, there is strong prior reason to think that one dose is likely to work well, and that a second shot in the distant future would be even better than a second shot after three or four weeks. Booster shots are given a.) as backup for people who don't seroconvert after one dose b.) to trigger a secondary immune response. In light of a.), we shouldn't be surprised by the 85% number (most people seroconvert; there's no partial immunity, you either seroconvert or you don't). In light of b.), we should be very skeptical of the four week interval, especially since the secondary response takes about two weeks to develop. It's shorter than the interval for every other vaccine.
[1] https://arstechnica.com/science/2020/12/fda-releases-data-on... [2] https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolesc...
Yes, two doses are almost certainly better than one. But those are not the choices.
When there are far fewer doses than the number of people to vaccinate, the question is if it's better to give N people 2 shots, or 2N people 1 shot.
The test data looks like 1 dose gives ~80% protection vs ~95% for 2 doses. The 2x80% scenario is clearly better than 1x95%.
And, of course, everyone would get the second dose as soon as production catches up.
https://www.statnews.com/2021/01/04/britain-takes-a-gamble-w...
That the impact could be huge doesn't take much imagination: We could be back to square 1 with the vaccination process and the evolved virus might be more dangerous.
That's not quite true. You need 2 for full effectiveness, but it's not like missing the second dose leaves you with no benefit at all. In fact, it's far from clear, from a global perspective, that having twice as many people with less-than-full-effectiveness would not better than half as many people with full effectiveness.